Krystal Biotech
KRYS
57 hedge funds and large institutions have $223M invested in Krystal Biotech in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
73% more capital invested
Capital invested by funds: $129M → $223M (+$94.1M)
27% more funds holding
Funds holding: 45 → 57 (+12)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
3.51% more ownership
Funds ownership: 43.03% → 46.53% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.98M |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$1.46M |
| 4 |
O
OrbiMed
New York
|
+$1.4M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$2.12M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$979K |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$466K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$287K |
| 5 |
Renaissance Technologies
New York
|
-$262K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $188K | +$130K | +5,530 | +2,973% |
|
|
DMK
52
David M. Knott
| $121K | +$51.5K | +2,184 | +145% |
|
53
KBC Group
Brussels,
Belgium
| $108K | +$8.25K | +350 | +12% |
|
54
Morgan Stanley
New York
| $63K | -$49.1K | -2,085 | -52% |
|
|
CSS
55
Cubist Systematic Strategies
Stamford,
Connecticut
| $16K | +$11.8K | +500 | New |
|
|
DWA
56
Dorsey Wright & Associates
Pasadena,
California
| $11K | -$8.06K | -342 | -50% |
|
57
Federated Hermes
Pittsburgh,
Pennsylvania
| $4K | -$19.7K | -834 | -87% |
|
|
58
Invesco
Atlanta,
Georgia
| – | -$979K | -47,113 | Closed |
|
|
MCM
59
Moore Capital Management
New York
| – | -$260K | -12,500 | Closed |
|
|
BFM
60
Boothbay Fund Management
New York
| – | -$209K | -10,038 | Closed |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | -$24K | -1,140 | Closed |
|
62
UBS Group
Zurich,
Switzerland
| – | -$14K | -675 | Closed |
|
KRYS Hedge Fund Activity: Q1 2019 in Review
57 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2019, worth a combined $223M — up 73% from $129M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KRYS positions and 5 closed out — a net gain of 12 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.1M. The largest seller was Knoll Capital Management, cutting an estimated $2.12M.
- 57 institutional investors held Krystal Biotech (KRYS) as of Q1 2019, up from 45 in Q4 2018.
- Funds reported $223M of Krystal Biotech stock for Q1 2019, up 73% quarter-over-quarter.
- 17 funds opened new Krystal Biotech positions in Q1 2019 and 5 closed out, a net change of +12 holders.
- The largest Krystal Biotech buyer in Q1 2019 was Millennium Management, an estimated $2.1M added.
- The largest Krystal Biotech seller in Q1 2019 was Knoll Capital Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q1 2019.